REVIEW

4475  Colon mucus in colorectal neoplasia and beyond  
Loktionov A

MINIREVIEWS

4493  Who to screen and how to screen for celiac disease  
Singh P, Singh AD, Ahuja V, Makharia GK

4508  Assessment of physical stress during the perioperative period of endoscopic submucosal dissection  
Chinda D, Shimoyama T

4516  Expanding beyond endoscopy: A review of non-invasive modalities in Barrett’s esophagus screening and surveillance  
Shahsavari D, Kudaravalli P, Yap JEL, Vega KJ

4527  Impact of microbiota-immunity axis in pancreatic cancer management  
Bartolini I, Nannini G, Risaliti M, Matarazzo F, Moraldi L, Ringressi MN, Taddei A, Amedei A

4540  Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview  
Liava C, Sinakos E, Papadopoulou E, Giannakopoulou L, Potsi S, Mountzouoglou A, Chatziioannou A, Stergioulas L, Kalogeropoulou L, Dedes I, Akriviadis E, Chourmouzi D

4557  Liver regeneration as treatment target for severe alcoholic hepatitis  

ORIGINAL ARTICLE

Basic Study

4574  Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-xB pathway and microbiota regulation  
Lu DX, Liu F, Wu H, Liu HX, Chen BY, Yan J, Lu Y, Sun ZG

4600  Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma  
Zhou L, Zhao Y, Pan LC, Wang J, Shi XJ, Du GS, He Q

4620  Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model  
Yehya AHS, Subramaniam AV, Assif M, Kaur G, Abdul Majid AMS, Oon CE
The mechanism of Yinchenhao decoction in treating obstructive-jaundice-induced liver injury based on Nrf2 signaling pathway
Liu JJ, Xu Y, Chen S, Hao CF, Liang J, Li ZL

Anoctamin 5 regulates the cell cycle and affects prognosis in gastric cancer

Effects of Granule Dendrobii on chronic atrophic gastritis induced by N-methyl-N’-nitro-N-nitrosoguanidine in rats
Wu Y, Li Y, Jin XM, Dai GH, Chen X, Tong YL, Ren ZM, Chen Y, Xue XM, Wu RZ

Retrospective Study
Machine learning predicts portal vein thrombosis after splenectomy in patients with portal hypertension: Comparative analysis of three practical models

Observational Study
International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis
Ilic I, Ilic M

Prospective Study
Differential diagnosis of different types of solid focal liver lesions using two-dimensional shear wave elastography
Guo J, Jiang D, Qian Y, Yu J, Gu YJ, Zhou YQ, Zhang HP

META-ANALYSIS
Use of shear wave elastography for the diagnosis and follow-up of biliary atresia: A meta-analysis
Wagner ES, Abdelgawad HAH, Landry M, Asfour B, Slidell MB, Azzam R

LETTER TO THE EDITOR
Is endoscopic mucosal ablation a valid option for treating colon polyps?
Liu XY, Ren RR, Wu C, Wang LY, Zhu ML
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, PhD, MD, Associate Professor in Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples 80130, Italy. caterina.sagnelli@unicampania.it

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.
Basic Study

Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model

Ashwaq Hamid Salem Yehya, Ayappa V Subramaniam, Muhammad Asif, Gurjeet Kaur, Amin M S Abdul Majid, Chern Ein Oon

Specialty type: Integrative and complementary medicine

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report’s scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Hamaya Y, Japan; Matsumoto T, Japan

Received: January 10, 2022
Peer-review started: January 10, 2022
First decision: April 16, 2022
Revised: April 26, 2022
Accepted: June 26, 2022
Article in press: June 26, 2022
Published online: July 28, 2022

Ashwaq Hamid Salem Yehya, Ayappa V Subramaniam, Gurjeet Kaur, Chern Ein Oon, Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, Malaysia

Ashwaq Hamid Salem Yehya, Cancer Research, Eman Biodiscoveries, Kedah 08000, Malaysia

Muhammad Asif, Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab 63100, Pakistan

Amin M S Abdul Majid, Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australia 2601, Australia

Corresponding author: Chern Ein Oon, PhD, Associate Professor, Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Chancellory II, Penang 11800, Malaysia. chern.oon@usm.my

Abstract

Pancreatic cancer is the most aggressive cancer type. Gemcitabine is the first line chemo-drug used for pancreatic cancer but exerts a broad spectrum of organ toxicities and adverse effects in patients.

AIM

To evaluate the anti-tumour activity and toxicological effects of Orthosiphon stamineus extract formulation (ID: C5EOSEW5050ESA trademarked as Nuva-static®) and gemcitabine combination on pancreatic xenograft model.

METHODS

Mice were randomly divided into six groups of 6 mice each (n = 6) and given different treatments for 28 d. The study design consisted of a 2 x 3 factorial treatment structure, with gemcitabine (yes/no) by oral (at 1200 and 400 mg/kg per day). Human pancreatic cancer cells were injected subcutaneously into the flanks of athymic nude mice. C5EOSEW5050ESA (200 or 400 mg/kg per day) was administered orally, while gemcitabine (10 mg/kg per 3 d) was given intraperitoneally either alone or in combination treatment. Histopathological analyses of vital organs, tumour tissues, and incidence of lethality were analysed. Analyses of
tumour necrosis and proliferation were determined by haematoxylin-eosin staining and immunohistochemistry for Ki-67, respectively.

RESULTS
No signs of toxicity or damage to vital organs were observed in all treatment groups compared to the untreated group. C5EOSEW5050ESA at 200 mg/kg and gemcitabine combination had no additive antitumor effects compared to a single treatment. Remarkably, a comparably greater response in a reduction in tumour growth, Ki-67 protein expression, and necrosis was demonstrated by 400 mg/kg of C5EOSEW5050ESA and gemcitabine combination than that of the individual agents.

CONCLUSION
These results highlighted the synergistic activity of C5EOSEW5050ESA with gemcitabine to reduce pancreatic tumour growth in mice compared to a single treatment. Thus, this study provides valuable insights into using C5EOSEW5050ESA as a complementary treatment with gemcitabine for pancreatic cancer.

Key Words: Pancreatic cancer; Orthosiphon stamineus; C5EOSEW5050ESA; Gemcitabine; Complementary medicine

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The combination of C5EOSEW5050ESA at 400 mg/kg and gemcitabine synergistically reduced tumour growth compared to either drug alone by reducing Ki-67 cell proliferation marker and tumour necrosis. In addition, no signs of toxicity or damage to vital organs in single C5EOSEW5050ESA or gemcitabine and chemo-herbal combinations treated animals compared to the untreated group, indicating the safety and efficacy of the combination treatment in a short term study. Findings from this study may provide the basis for product formulation and manufacturing of botanical drugs to be used as complementary medicine for the treatment of cancer.

INTRODUCTION
Pancreatic cancer is one of the deadliest cancers globally and has the most unfavourable survival rate of any cancer[1]. Chemotherapy, radiation, surgery, and molecular targeting agents are common strategies to treat pancreatic cancer. However, the majority of these systemic treatments are associated with severe side effects[1]. Gemcitabine, a nucleoside analogue of cytidine, is the first line of treatment used to treat pancreatic cancer[2]. However, its overall success rates are poor. In addition, combination treatments of gemcitabine with other chemo-drugs, such as capectabine, irinotecan, oxaliplatin, and cisplatin, may cause multiple adverse reactions and drug resistance, leading to a reduction of drug efficacy[3].

Herbal products have been traditionally used to treat many diseases in Asian countries[4]. Data from pre-clinical and clinical studies have also highlighted that these natural herbs, when combined with conventional radio- or chemotherapies, can sensitise tumour cells to treatments to improve cancer patients' survival and quality of life[5,6]. Nevertheless, this is not always the case, as studies have also shown that herbal medicines, when combined with chemotherapy, may instead enhance the toxicity potential of chemo drugs, leading to increased incidences of severe side effects[7].

Therefore, understanding the interactions of herbal-chemo drugs is necessary for the appropriate use of these combinations to prevent the emergence of toxicity and therapeutic failure in cancer patients. Orthosiphon stamineus (O.s) is a traditional Asian herbal medicine used to treat various diseases, including cancers[8]. The safety profile of O.s has already been established globally by numerous research groups using in vivo and in vitro models[3,9]. Our research group has already established the antitumor efficacy of O.s against colon cancer[9,10]. C5OSEW5050ESA (Nuvastatic™) is a proprietary extract of O.s that completed a phase 2/3 clinical study for cancer fatigue in cancer patients with solid tumours receiving chemotherapy[11]. However, no study has reported the toxicity profile of C5OSEW5050ESA in a pancreatic cancer xenograft model as a stand-alone or in combination with
Table 1 Treatment conditions for 28 d

<table>
<thead>
<tr>
<th>No.</th>
<th>Group</th>
<th>The route of treatment and dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Group I (untreated group- distilled water)</td>
<td>Oral (1 mg/kg per day)</td>
</tr>
<tr>
<td>2</td>
<td>Group II (chemodrug-gemcitabine)</td>
<td>Intraperitoneal (10 mg/kg per 3 d)</td>
</tr>
<tr>
<td>3</td>
<td>Group III (low dose of O.s)</td>
<td>Oral (200 mg/kg per day)</td>
</tr>
<tr>
<td>4</td>
<td>Group IV (low dose of O.s -gemcitabine combination)</td>
<td>Oral (200 mg/kg per day) + Intraperitoneal (10 mg/kg per 3 d)</td>
</tr>
<tr>
<td>5</td>
<td>Group V (high dose of O.s)</td>
<td>Oral (400 mg/kg per day)</td>
</tr>
<tr>
<td>6</td>
<td>Group VI (high dose of O.s-gemcitabine combination)</td>
<td>Oral (400 mg/kg per day) + Intraperitoneal (10 mg/kg per 3 d)</td>
</tr>
</tbody>
</table>

M.S: Orthosiphon stamineus.

gemcitabine. We have previously reported that the combination treatment of O.s and gemcitabine showed no toxicity in mice, either as a stand-alone or in combination[3]. Furthermore, O.s significantly sensitised Panc-1 towards gemcitabine in vitro[4]. Consequently, the present study was designed to evaluate the toxicological effects of Nuvastatic™ and gemcitabine either alone or in combination using the pancreatic cancer nude mice model.

MATERIALS AND METHODS

Plant materials and chemicals
Orthosiphon stamineus extract (C5EOSEW5050ESA) was purchased from NatureCeutical Sdn Bhd, Malaysia. Gemcitabine (Catalogue No. S1149) was obtained from Selleckchem, Houston, TX, United States. C5EOSEW5050ESA was dissolved in sterile distilled water and filtered by a membrane filter unit (0.22 µm). C5EOSEW5050ESA was administered orally to mice, while gemcitabine was given via intraperitoneal injection after being dissolved in phosphate buffer saline (PBS).

Animals
Male athymic nude mice (procured from iDNA, Malaysia) were kept in filter-top cages under controlled atmospheric conditions at the EMAN Testing and Research laboratory, School of Pharmaceutical Sciences, USM. Autoclaved food, water, and bedding of cages were changed every 48 h. The animal study was approved and conducted under strict guidelines according to USM Animal Ethics Committee (Reference #: USM/Animal Ethics Approval/2016/(97) (746).

Cell lines
Panc-1, a pancreatic cancer cell line, was purchased from American Type Culture Collection (ATCC). The cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Scientific, United States) supplemented with 10% fetal bovine serum (Biowest, United States) and 100 units/mL penicillin-streptomycin (Nacalai Tesque, United States). Cells were kept at 37 °C in a humidified incubator with 5% CO2 atmosphere.

In vivo assessment of tumour growth in a nude mouse xenograft model: Panc-1 cells (20 × 10^6 cells suspended in 200 µL of a mixture of DMEM and matrigel in a 1:1 ratio) were injected subcutaneously on the dorsal side of each mouse. Treatment with gemcitabine and O.s in different combinations or as a stand-alone was initiated when at least three of the tumours in any group reached 100 mm^3.

Experimental treatment design
Mice were randomly divided into six groups of 6 mice each (n = 6) and given different treatments for 28 d, as mentioned in Table 1. The body weight of all mice and tumour size was measured every 3rd day. At the end of the study, all the mice were euthanised with a combination of ketamine and xylazine when the tumour volumes from the untreated group reached 1000 mm^3. The blood samples were collected for haematological and serum biochemical tests. Organs (liver, kidney, and spleen) were harvested and weighed to observe the changes in the organ weights of treated animals compared to the untreated group. Tumour tissues and organs were collected and fixed with 10% buffered formalin. Paraffin blocks were prepared, and sections of 5 µm were stained with haematoxylin and eosin (HE). Ten microscopic fields per slide were examined at × 20 and × 40 magnification, and photomicrographic images were captured using a digital camera.
**Blood parameters and biochemical tests**

Blood samples were used to measure different haematological parameters, including haemoglobin (Hb) levels, total blood count, differential counting of white blood cells, packed cell volume (PCV), mean cell volume (MCV), mean cell haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), red cell distribution width (RDW), creatinine, urea, uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, cholesterol (low and high-density cholesterol), triglycerides, total protein, albumin, globulin, albumin/globulin ratio, and minerals (sodium, potassium, and chloride).

**Histopathological examination**

Key organs (liver, kidney, and spleen) were harvested and fixed in a 10% buffered formaldehyde solution. An automated tissue processing machine then processed the fixed tissues and embedded them in paraffin wax to prepare sample blocks.

**Haematoxylin and eosin staining**

Tissue sections of 5 mm thickness were cut and prepared at 60 ºC. The slides were dewaxed in xylene and rehydrated through graded alcohol. Slides were rinsed and incubated with haematoxylin for 4 min. After rinsing, eosin was added to the slides for 1 min. Next, slides were rinsed in tap water and briefly air-dried at room temperature. Slides were then mounted with glycerol (Sigma, United States). Stained slides were examined and scored for the percentage of necrosis within the tumour areas by a pathologist (GK) under a light microscope.

**Immunohistochemistry staining**

The formalin-fixed-paraffin-embedded (FFPE) tissue sections were prepared at 60 ºC, dewaxed in xylene, and rehydrated through graded alcohol. Antigens were retrieved using Dako’s antigen retrieval buffer (1 ×, pH 9.0) and then microwaved on high for 15 min. Slides were cooled, washed and then blocked with hydrogen peroxidase and BSA. Then slides were treated with primary antibody Ki67 (Dako, Glostrup, Denmark) and left to incubate at 4 ºC overnight at 1:50 dilution. The next day, slides were treated with secondary antibody goat anti-mouse (Dako, Glostrup, Denmark) for 1 h at 1:500 dilution. After that, Dab stain (Dako, Glostrup, Denmark) and haematoxylin were added to the slides. Finally, slides were air-dried at room temperature and mounted with glycerol (Sigma, United States). Using ImageJ, the Ki-67 score was determined as the percentage of tumour cells that showed brown nuclear staining over the total number of nuclei from five random fields per tumour section.

**Statistical analysis**

Graphing software Excel (Microsoft, United States) and Prism (GraphPad, United States) were used for statistical analysis. Data were presented as mean ± SD whereas the parametric data analysis was performed using a one-way analysis of variance (ANOVA). Two-way ANOVA was used to understand if there is an interaction between the two independent variables on the dependent variable. The Tukey’s honest significant difference (HSD) post hoc test was used to assess the significant differences among all groups. Analysis for non-parametric data was performed using Kruskal-Wallis ANOVA. A value of $P < 0.05$ was considered significant when compared to values in the respective untreated group.

**RESULTS**

**Effect of treatment on mouse body weight and key organs**

C5EOSEW5050ESA demonstrated no toxicity in mice: The average body weight within the untreated group increased compared to other treatment groups (Table 2). However, there was no notable difference in body weight between untreated groups and other treatment groups (Table 2). In addition, the weight of vital organs, including the kidney, liver, and spleen, remained unchanged post-treatment with either C5EOSEW5050ESA and/or gemcitabine (Table 3).

**Haematological-biochemical parameters and electrolyte profiles:** No significant changes were observed in the Hb level, total blood cells count, or differential counting of WBC, PCV, MCV, MCH, MCHC, and RDW when compared with the corresponding parameters in the untreated group (Table 4). No significant changes were noted in serum parameters, i.e. creatinine, urea, uric acid, AST, ALT, ALP, GGT, total bilirubin, total protein, albumin, globulin, and albumin/globulin ratio, which were observed in animal groups treated with C5EOSEW5050ESA at (200 or 400 mg/kg, per day) alone or in combination with gemcitabine (10 mg/kg per 3 d) after 28 d treatment when compared to the untreated group (Table 5). Normal ALT, ALP, and AST levels in the serum indicate that there is no damage in hepatocytes. Similarly, urea and total bilirubin levels were also within the normal range, indicating the lack of toxicity in the kidneys when treated with C5EOSEW5050ESA and gemcitabine either alone or in
Table 2 Effect of C5EOSEW5050ESA and gemcitabine alone or in combination on mouse body weight

<table>
<thead>
<tr>
<th>No.</th>
<th>Group</th>
<th>Days</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>Untreated</td>
<td>24.2 ± 0.8</td>
<td>24.5 ± 1.0</td>
</tr>
<tr>
<td>2</td>
<td>Gemcitabine (10 mg/kg per 3 d)</td>
<td>24.2 ± 0.7</td>
<td>24.3 ± 1.5</td>
</tr>
<tr>
<td>3</td>
<td>O.s (200 mg/kg per day)</td>
<td>23.6 ± 0.6</td>
<td>23.9 ± 0.7</td>
</tr>
<tr>
<td>4</td>
<td>O.s (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>24.0 ± 0.8</td>
<td>24.0 ± 1.2</td>
</tr>
<tr>
<td>5</td>
<td>O.s (400 mg/kg per day)</td>
<td>24.2 ± 0.7</td>
<td>24.4 ± 0.8</td>
</tr>
<tr>
<td>6</td>
<td>O.s (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>23.9 ± 0.7</td>
<td>24.0 ± 0.2</td>
</tr>
</tbody>
</table>

Each group contains 6 mice. The results showed no significant difference in the reduction of body weight of mice compared to the untreated group. Data are represented as mean ± SD. (NS: Not significant compared to the untreated group, P > 0.05). No statistical difference was also observed among all treatment groups using Two-way ANOVA and Tukey’s honest significant difference posthoc test. O.s: Orthosiphon stamineus.

Table 3 Effect of C5EOSEW5050ESA and gemcitabine alone or in combination on mouse key organ weight

<table>
<thead>
<tr>
<th>No.</th>
<th>Group</th>
<th>Days</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>Untreated</td>
<td>1.7 ± 0.22</td>
<td>0.47 ± 0.06</td>
</tr>
<tr>
<td>2</td>
<td>Gemcitabine (10 mg/kg per 3 d)</td>
<td>1.7 ± 0.23</td>
<td>0.46 ± 0.06</td>
</tr>
<tr>
<td>3</td>
<td>O.s (200 mg/kg per day)</td>
<td>1.67 ± 0.23</td>
<td>0.47 ± 0.06</td>
</tr>
<tr>
<td>4</td>
<td>O.s (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>1.31 ± 0.25</td>
<td>0.41 ± 0.08</td>
</tr>
<tr>
<td>5</td>
<td>O.s (400 mg/kg per day)</td>
<td>1.37 ± 0.35</td>
<td>0.41 ± 0.09</td>
</tr>
<tr>
<td>6</td>
<td>O.s (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>1.43 ± 0.19</td>
<td>0.43 ± 0.09</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD (n = 6) (NS: Not significant compared to the untreated group, P > 0.05). No statistical difference was also observed among all treatment groups using two-way ANOVA and Tukey’s honest significant difference posthoc test. O.s: Orthosiphon stamineus.

Combination treatment (Table 5). Electrolytes were within the normal ranges in all the groups, with no significant changes observed compared to the untreated group (Table 5).

Histopathology analysis: Histopathological examination of formalin-fixed paraffin-embedded tissues of the spleen (Figure 1), kidney (Figure 2), and liver (Figure 3) of all treatment groups, as well as the untreated group, revealed normal histology without pathological evidence of inflammation or necrosis. In addition, the liver did not exhibit an accumulation of neutral fats or triglycerides within the liver cells. However, the liver cells demonstrated mild swelling in all groups except for C5EOSEW5050ESA (200 mg/kg per day) treatment group (Figure 3).

C5EOSEW5050ESA and gemcitabine combination synergistically inhibited pancreatic tumour growth in the xenograft model

Single treatments with gemcitabine at 10 mg/kg and C5EO-SEW5050ESA at 200 mg/kg or 400 mg/kg inhibited tumour growth and reduced tumour weight compared to the vehicle untreated group (Figures 4A and B). However, compared to a single treatment, no additive effect in inhibiting tumour growth and tumour weight was obtained with 200 mg/kg C5EOSE-W5050ESA combined with gemcitabine
Table 4 Haematological parameters in different treatment groups

<table>
<thead>
<tr>
<th>No.</th>
<th>Group</th>
<th>Hb, g/L</th>
<th>Total RBC as 10^12/L</th>
<th>PCV, L/L</th>
<th>MCV, fl</th>
<th>MCH, pg</th>
<th>MCHC, g/L</th>
<th>RDW, %</th>
<th>Total WBC as 10^9/L</th>
<th>N, %</th>
<th>L, %</th>
<th>M, %</th>
<th>E, %</th>
<th>B, %</th>
<th>Plts as 10^9/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Untreated</td>
<td>121 ± 1.0</td>
<td>7.9 ± 0.9</td>
<td>0.36 ± 0.0</td>
<td>46 ± 1.5</td>
<td>15 ± 0.7</td>
<td>332 ± 1.1</td>
<td>20.6 ± 1.0</td>
<td>5.8 ± 1.3</td>
<td>37 ± 1.0</td>
<td>55 ± 1.1</td>
<td>5 ± 0.8</td>
<td>2 ± 0.1</td>
<td>1 ± 0.0</td>
<td>790 ± 1.2</td>
</tr>
<tr>
<td>2</td>
<td>Gemcitabine (10 mg/kg per 3 d)</td>
<td>118 ± 1.4</td>
<td>7.60 ± 1.1</td>
<td>0.38 ± 0.0</td>
<td>50.0 ± 1.8</td>
<td>16.0 ± 0.6</td>
<td>313 ± 1.8</td>
<td>22.1 ± 0.7</td>
<td>6.0 ± 1.2</td>
<td>33.0 ± 1.2</td>
<td>60.0 ± 0.7</td>
<td>6.0 ± 1.3</td>
<td>1.0 ± 0.1</td>
<td>0.0 ± 0.1</td>
<td>720 ± 1.4</td>
</tr>
<tr>
<td>3</td>
<td>O.s (200 mg/kg per day)</td>
<td>118 ± 1.5</td>
<td>8.0 ± 0.8</td>
<td>0.38 ± 0.0</td>
<td>48.0 ± 2.0</td>
<td>15.0 ± 1.1</td>
<td>307 ± 0.9</td>
<td>22.3 ± 1.6</td>
<td>6.10 ± 0.7</td>
<td>35.0 ± 0.8</td>
<td>53.0 ± 0.6</td>
<td>9.0 ± 1.0</td>
<td>1.0 ± 0.1</td>
<td>2.0 ± 0.0</td>
<td>801 ± 0.8</td>
</tr>
<tr>
<td>4</td>
<td>O.s (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>115 ± 1.7</td>
<td>7.1 ± 1.4</td>
<td>0.35 ± 0.0</td>
<td>50.0 ± 1.6</td>
<td>16.0 ± 0.7</td>
<td>321 ± 1.5</td>
<td>21.5 ± 0.8</td>
<td>5.70 ± 1.5</td>
<td>32.0 ± 0.9</td>
<td>60.0 ± 1.1</td>
<td>5.0 ± 0.7</td>
<td>2.0 ± 0.1</td>
<td>1.0 ± 0.1</td>
<td>760 ± 0.9</td>
</tr>
<tr>
<td>5</td>
<td>O.s (400 mg/kg per day)</td>
<td>123 ± 1.6</td>
<td>7.9 ± 0.7</td>
<td>0.36 ± 0.0</td>
<td>46.0 ± 1.5</td>
<td>16.0 ± 1.6</td>
<td>335 ± 2.0</td>
<td>21.0 ± 0.9</td>
<td>5.70 ± 1.8</td>
<td>33.0 ± 1.2</td>
<td>61.0 ± 1.2</td>
<td>4.0 ± 0.6</td>
<td>2.0 ± 0.1</td>
<td>0.0 ± 0.0</td>
<td>740 ± 1.0</td>
</tr>
<tr>
<td>6</td>
<td>O.s (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>123 ± 1.1</td>
<td>7.70 ± 0.9</td>
<td>0.36 ± 0.0</td>
<td>47.0 ± 1.2</td>
<td>16.0 ± 0.4</td>
<td>331 ± 1.2</td>
<td>22.6 ± 1.3</td>
<td>6.0 ± 1.5</td>
<td>30.0 ± 0.9</td>
<td>60.0 ± 1.1</td>
<td>8.0 ± 1.3</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.0</td>
<td>810 ± 1.3</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± SD (n = 6). The P values in all treated groups were insignificant compared to the untreated group. No statistical difference was also observed among all treatment groups using two-way ANOVA and Tukey’s honest significant difference posthoc test. B: Basophile; E: Eosinophile; Hb: Haemoglobin; L: Lymphocyte; M: Monocyte; MCH: Mean cell haemoglobin; MCHC: Mean cell haemoglobin concentration; MCV: Mean cell volume; N: Neutrophile; O.s: Orthosiphon stamineus; PCV: Packed cell volume; Plts: Platelets; RBC: Red blood cells; RDW: Red cell distribution width; WBC: White blood cells.

(Figure 4A and B). However, C5EOSEW5050ESA at 400 mg/kg combined with gemcitabine significantly reduced tumour growth and tumour weight compared to individual treatment groups (Figures 4A and B).

C5EOSEW5050ESA and gemcitabine combination synergistically inhibited pancreatic tumour necrosis in the xenograft model: A single treatment with gemcitabine at 10 mg/kg and C5EOSEW5050ESA at 200 mg/kg or 400 mg/kg reduced tumour necrosis compared to untreated tumour cells (Figure 5). No additive effect in reducing tumour necrosis was obtained with C5EOSEW5050ESA at 200 mg/kg and gemcitabine combination compared to a single treatment (Figure 5D). However, C5EOSEW5050ESA at 400 mg/kg and gemcitabine combination significantly reduced tumour necrosis compared to single treatment groups of the respective doses (Figure 5).

C5EOSEW5050ESA combined with gemcitabine synergistically inhibited Ki67 protein expression in pancreatic tumour tissue: Ki67 proliferative marker protein was highly expressed in the untreated group compared to all treatment groups (Figure 6). Compared to a single treatment, no additive effect in reducing Ki67 protein expression was obtained with 200 mg/kg C5EOSEW5050ESA and gemcitabine combination (Figure 6). However, 400 mg/kg C5EOSEW5050ESA and gemcitabine combination synergistically inhibited the expression of Ki67 protein compared to single treatment and other treatment groups (Figure 6).
### Table 5 Blood biochemical parameters and electrolyte profiles in different treatment groups

<table>
<thead>
<tr>
<th>No.</th>
<th>Group</th>
<th>Creatinine, mmol/L</th>
<th>Urea, mmol/L</th>
<th>Uric acid, mmol/L</th>
<th>AKT, U/L</th>
<th>AST, U/L</th>
<th>ALT, U/L</th>
<th>GGT, U/L</th>
<th>Total protein, g/L</th>
<th>Albumin, g/L</th>
<th>Globulin, g/L</th>
<th>Albumin/ Globulin ratio</th>
<th>Total Bilirubin, µmol/L</th>
<th>Na</th>
<th>K</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Untreated</td>
<td>28.1 ± 1.5</td>
<td>8.80 ± 0.9</td>
<td>0.20 ± 0.0</td>
<td>96.0 ± 0.5</td>
<td>195 ± 0.7</td>
<td>73.0 ± 0.7</td>
<td>&lt; 3.0 ± 0.0</td>
<td>50.0 ± 0.5</td>
<td>30.0 ± 1.1</td>
<td>23.0 ± 0.5</td>
<td>1.40 ± 0.3</td>
<td>2.00 ± 0.0</td>
<td>178 ± 0.3</td>
<td>8.00 ± 0.7</td>
<td>124 ± 1.1</td>
</tr>
<tr>
<td>2</td>
<td>Gemcitabine (10 mg/kg per 3 d)</td>
<td>28.0 ± 1.9</td>
<td>9.00 ± 1.1</td>
<td>0.16 ± 0.1</td>
<td>93.0 ± 1.3</td>
<td>190 ± 0.9</td>
<td>72.0 ± 0.9</td>
<td>&lt; 3.0 ± 0.0</td>
<td>52.0 ± 1.2</td>
<td>32.0 ± 0.7</td>
<td>24.0 ± 0.7</td>
<td>1.40 ± 0.2</td>
<td>2.00 ± 0.0</td>
<td>173 ± 0.5</td>
<td>9.30 ± 0.4</td>
<td>123 ± 0.2</td>
</tr>
<tr>
<td>3</td>
<td><em>O.s</em> (200 mg/kg per day)</td>
<td>29.0 ± 1.5</td>
<td>9.20 ± 1.3</td>
<td>0.19 ± 0.0</td>
<td>98.0 ± 1.2</td>
<td>201 ± 1.1</td>
<td>80.0 ± 1.1</td>
<td>&lt; 3.0 ± 0.0</td>
<td>50.5 ± 0.7</td>
<td>33.0 ± 0.3</td>
<td>23.0 ± 0.7</td>
<td>1.30 ± 0.3</td>
<td>2.00 ± 0.0</td>
<td>174 ± 0.8</td>
<td>9.00 ± 0.8</td>
<td>128 ± 0.9</td>
</tr>
<tr>
<td>4</td>
<td><em>O.s</em> (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>27.5 ± 1.1</td>
<td>9.50 ± 0.9</td>
<td>0.21 ± 0.1</td>
<td>101 ± 0.9</td>
<td>210 ± 0.7</td>
<td>77.0 ± 0.7</td>
<td>&lt; 3.0 ± 0.0</td>
<td>51.3 ± 1.1</td>
<td>29.9 ± 0.9</td>
<td>22.5 ± 0.9</td>
<td>1.30 ± 0.2</td>
<td>2.00 ± 0.0</td>
<td>186 ± 0.9</td>
<td>8.60 ± 0.6</td>
<td>130 ± 1.1</td>
</tr>
<tr>
<td>5</td>
<td><em>O.s</em> (400 mg/kg per day)</td>
<td>28.5 ± 0.9</td>
<td>8.80 ± 0.7</td>
<td>0.22 ± 0.1</td>
<td>101 ± 0.7</td>
<td>199 ± 0.9</td>
<td>66.0 ± 0.5</td>
<td>&lt; 3.0 ± 0.0</td>
<td>51.9 ± 0.5</td>
<td>32.4 ± 0.8</td>
<td>25.0 ± 0.9</td>
<td>1.40 ± 0.2</td>
<td>2.00 ± 0.0</td>
<td>190 ± 0.4</td>
<td>10.0 ± 0.5</td>
<td>133 ± 0.9</td>
</tr>
<tr>
<td>6</td>
<td><em>O.s</em> (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination</td>
<td>27.0 ± 0.8</td>
<td>8.50 ± 1.3</td>
<td>0.21 ± 0.0</td>
<td>101 ± 0.8</td>
<td>190 ± 0.7</td>
<td>70.0 ± 0.9</td>
<td>&lt; 3.0 ± 0.0</td>
<td>52.0 ± 0.7</td>
<td>30.5 ± 0.6</td>
<td>24.0 ± 0.7</td>
<td>1.40 ± 0.1</td>
<td>2.00 ± 0.0</td>
<td>185 ± 0.6</td>
<td>9.80 ± 0.9</td>
<td>123 ± 0.5</td>
</tr>
</tbody>
</table>

Results are expressed as the mean ± SD (n = 6). The P values in all treated groups were insignificant compared to the untreated group. No statistical difference was also observed among all treatment groups using two-way ANOVA and Tukey’s honest significant difference posthoc test. AKT: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CL: Chloride; GGT: Gamma-glutamyl transferase; K: Potassium; Na: Sodium; *O.s*: Orthosiphon stamineus.

## DISCUSSION

Studies have shown that therapeutic combinations containing low-dose marketed drugs and plant extracts/isolated compounds or essential oils may improve the safety profile of marketed drugs and produce synergistic actions[12,13]. The safety profile of C5EOSEW5050ESA has previously been established[14,15], with its LD₅₀ values reported to be greater than 5000 mg/kg[15]. Chemo-herbal combinations are one of the possible therapeutic options which can be employed to improve the efficacy of a drug, reduce adverse drug effects and increase disease-free intervals and overall survival rates in cancer patients. The majority of chemotherapeutic drugs destroy tumours and retard cancer growth but may also damage healthy tissues. Thus, new chemo-herbal combinations are anticipated to play an essential role in developing more effective and safer strategies to inhibit cancer progress with minimal side effects[4].

We have previously shown the synergistic anti-cancer effects of combined C5EOSEW5050ESA and gemcitabine treatment on Panc-1 and MiaPaCa-2 pancreatic cancer cell lines[3]. Moreover, no toxicity was observed in mice in an acute toxicity study[3]. In the current study, the combination treatment in a pancreatic tumour xenograft model revealed no abnormal signs in any of the treatment groups (Figures 1-3). Moreover, no significant difference in organ weight change was noted when compared to the untreated group.

---

**Yehya AHS et al.** *Orthosiphon stamineus* and gemcitabine combination for pancreatic cancer

WJG [https://www.wjgnet.com](https://www.wjgnet.com)
Yehya AHS et al. *Orthosiphon stamineus* and gemcitabine combination for pancreatic cancer

Figure 1 Tissue sections of mice spleen stained with haematoxylin and eosin. Tissue sections from untreated and treated groups showed normal spleen architecture. A: Untreated; B: Gemcitabine (10 mg/kg per 3 d); C: C5EOSEW5050ESA (200 mg/kg per day); D: C5EOSEW5050ESA (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination; E: C5EOSEW5050ESA (400 mg/kg per day); F: C5EOSEW5050ESA (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination.

Figure 2 Tissue sections of mice kidneys stained with haematoxylin and eosin. Tissue sections showed normal glomeruli and tubules in all treated groups and untreated. A: Untreated; B: Gemcitabine (10 mg/kg per 3 d); C: C5EOSEW5050ESA (200 mg/kg per day); D: C5EOSEW5050ESA (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination; E: C5EOSEW5050ESA (400 mg/kg per day); F: C5EOSEW5050ESA (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination.

Untreated group, supporting the relatively safe nature of selected chemo-herbal combinations (Table 3). Clinical biochemistry and haematological analyses play a significant role in evaluating the signs of toxicity induced by drugs[16]. No significant alterations in haematological parameters were observed in the animal blood samples treated with C5EOSEW5050ESA and gemcitabine combination, indicating...
Figure 3 Tissue sections of mice liver stained with haematoxylin and eosin. Liver sections showed normal architecture with distinct hepatic cells, sinusoidal spaces, and a central vein in all treatment groups and untreated; mild hepatocellular swelling is seen in all groups except the C5EOSEW5050ESA (200 mg/kg per day) group where no swelling is present. A: Untreated; B: Gemcitabine (10 mg/kg per 3 d); C: C5EOSEW5050ESA (200 mg/kg per day); D: C5EOSEW5050ESA (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination; E: C5EOSEW5050ESA (400 mg/kg per day); F: C5EOSEW5050ESA (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination.

that these combinations did not damage the blood cells (Table 4). Increased serum bilirubin concentration and occurrence of tissue haemolysis are commonly seen when the liver is impaired[17]. The absence of these observations in the current study demonstrated the non-toxic effects of the C5EOSEW5050ESA gemcitabine combination on haemoglobin metabolic pathways (Table 4). A slight drop in white blood count and platelets and mild myelosuppression have been reported with extended treatment duration and high doses of gemcitabine[18]. In 2013, the MPACT phase III trial, which included over 800 patients, showed a significant overall survival benefit with the combination of nanomolecular albumin-bound (nab)-paclitaxel and gemcitabine (nabPGem) over gemcitabine monotherapy, with acceptable toxicity. The overall toxicity of nabPGem is lower than in the triple chemotherapy 5-FU, leucovorin, irinotecan and oxaliplatin, especially haematotoxicity and rates of neutropenic fever[19,20]. However, the current study and our previous toxicity study revealed no reduction in white blood cells and platelets (Table 4)[3]. In fact, C5EOSEW5050ESA and gemcitabine combination at the higher dose enhanced its efficacy at reducing tumour growth without causing any side effects, at least in this short term study.

Kidneys are particularly vulnerable to high doses of drugs as they eradicate many drugs and their metabolites. Therefore, renal function tests measure various substances, including serum urea, serum creatinine, and albumin, to determine the current health of the kidneys[21]. In the present study, there was no nephrotoxicity observed, indicating the safe nature of chemo-herbal combinations. The results showed normal level concentrations of urea, creatinine, and albumin and were supported by the typical renal architecture of kidney sections (Figure 2).

Liver function tests, for such markers as ALT, AST, ALP, and GGT, are used to measure hepatocellular damage during illnesses[22]. There were no significant changes in the serum levels of AST, ALT, ALP, and GGT in all treatment groups (Table 5). In addition, the hepatocellular architecture appeared normal in all treatment groups (Figure 3).

As a single treatment, gemcitabine at 10 mg/kg and C5EOSEW5050ESA at 200 mg/kg or 400 mg/kg inhibited tumour growth compared to untreated mice (Figure 4). Compared to a single treatment, no additive inhibition of tumour growth was obtained with 200 mg/kg C5EOSEW5050ESA and gemcitabine combination (Figure 4). However, C5EOSEW5050ESA at 400 mg/kg and gemcitabine
Figure 4 Tumour growth curve of Panc-1 cells in subcutaneous pancreatic tumour growth in nude mice and tumour weight. Treatments were given when the tumours reached 100 mm$^3$. A: Untreated; B: Gemcitabine (10 mg/kg per 3 d); C: C5EOSEW5050ESA (200 mg/kg per day); D: C5EOSEW5050ESA (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination; E: C5EOSEW5050ESA (400 mg/kg per day); F: C5EOSEW5050ESA (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination. Combination treatment of 400 mg/kg C5EOSEW5050ESA and gemcitabine (F) synergistically reduced the tumour growth compared to a single treatment. The combination treatment of 400 mg/kg C5EOSEW5050ESA and gemcitabine (F) significantly reduced tumour weight compared to a single treatment. Error bars represent standard deviations. Statistics analysis (a $P < 0.05$; b $P < 0.01$; c $P < 0.001$, two-way ANOVA for tumour growth, one-way ANOVA with Tukey’s HSD posthoc test for tumour weight, $n = 6$ animals per group) using SPSS and GraphPad Prism 6.0 software.

The combination treatment of C5EOSEW5050ESA at a high dose and gemcitabine significantly reduced Ki67 protein expression in tumour cells compared to a single treatment (Figure 6), indicating reduced cell proliferation in the former group. The epigallocatechin-3-O-gallate (EGCG) polyphenol is enriched in C5EOSEW5050ESA extract. Others have reported EGCG to inhibit tumour growth and induce apoptosis in mice implanted with head, neck, and lung cancers by decreasing the Ki67 expression in tissues from the xenograft model and downregulating caspase-3, caspase-8, caspase-9, and Bax in mouse vascular smooth muscle cells [25,26]. Another study showed that resveratrol inhibited Ki67 expression in pancreatic cancer cells in vitro and in vivo by sensitising pancreatic cancer cells to gemcitabine treatment [25]. It is postulated that the polyphenols in C5EOSEW5050ESA may act synergistically with gemcitabine in the pancreatic tumour xenograft model. C5EOSEW5050ESA worked in synergy with gemcitabine to reduce pancreatic tumour growth and tumour necrosis in mice compared to a single treatment of either C5EOSEW5050ESA or gemcitabine. Thus, based on current findings, it is proposed that 50% ethanol extract of O.s has the potential to be used in combination with
This study provides preliminary scientific evidence about the safety profile of O.s derived extract C5EOSEW5050ESA present in Nuvastatic™ in combination with gemcitabine in an athymic nude mice model. Furthermore, this work demonstrated that C5EOSEW5050ESA extract in combination with gemcitabine is relatively safe in the acute toxicity study. Furthermore, the clinical efficacy and safety of Nuvastatic™ in cancer asthenia have been evaluated in phase III clinical trials (ClinicalTrials.gov, Identifier: NCT04546607). Therefore, Nuvastatic™ has the potential to be employed as a complementary treatment with gemcitabine to treat pancreatic cancer.

CONCLUSION

Figure 5 Tumour necrosis percentage in tumour tissues stained with haematoxylin and eosin. A: Untreated group; B: Gemcitabine (10 mg/kg per 3 d); C: Orthosiphon stamineus (O.s) (200 mg/kg per day); D: O.s (200 mg/kg per day) + gemcitabine (10 mg/kg per 3 d); E: O.s (400 mg/kg per day); F: O.s (400 mg/kg per day) + gemcitabine (10 mg/kg per 3 d); G: Estimated marginal means of necrosis. Combination treatment of 400 mg/kg C5EOSEW5050ESA with gemcitabine synergistically inhibited tumour necrosis compared to a single treatment. Arrows indicate the necrotic area in tumour sections. Error bars represent standard deviations. Statistics analysis (two-way ANOVA, n = 6 animals per group) using SPSS software. O.s: Orthosiphon stamineus.

gemcitabine to treat pancreatic cancer.
Figure 6 Ki67 proliferation protein expression in treated and untreated groups. A: Untreated group; B: Orthosiphon stamineus (O.s) (200 mg/kg per day); C: O.s (400 mg/kg per day); D: Gemcitabine (10 mg/kg per 3 d); E: O.s (200 mg/kg per day) + gemcitabine (10 mg/kg per 3 d); F: O.s (400 mg/kg per day) + gemcitabine (10 mg/kg per 3 d); G: Estimated marginal means of Ki67. Single treatment either by C5OSEW5050ESA or gemcitabine significantly reduced the Ki67 protein expression in tumour tissues compared to the untreated group. No significant reduction of Ki67 protein expression was noted between the groups treated by C5OSEW5050ESA 200 mg/kg per day and the gemcitabine combination. Combination treatment of C5OSEW5050ESA 400 mg/kg per day and gemcitabine synergistically reduced Ki67 protein expression in tumour tissue compared to a single treatment. Error bars represent standard deviations. Statistics analysis (Two-way ANOVA, n = 6 animals per group) using SPSS software. O.s: Orthosiphon stamineus.

ARTICLE HIGHLIGHTS

Research background
Gemcitabine is the cornerstone for pancreatic cancer but demonstrates adverse effects in patients. Orthosiphon stamineus (O.s) has been traditionally used to treat various diseases. C5OSEW5050ESA (Nuvastatic™) is a proprietary extract of O.s that completed a phase 2/3 clinical study for cancer fatigue in cancer patients with solid tumours receiving chemotherapy.

Research motivation
No study has reported the toxicity profile of C5OSEW5050ESA in a pancreatic tumour animal model either as a stand-alone or in combination with gemcitabine.

Research objectives
To determine the anti-tumour activity and potential toxicity of Nuvastatic™ and gemcitabine combination on pancreatic xenograft model.
Human pancreatic cancer cells were injected subcutaneously into athymic nude mice. C5EOSEW5050ESA (200 or 400 mg/kg per day) was administered orally, while gemcitabine (10 mg/kg/3 d) was given intraperitoneally either alone or in combination treatment. Histopathological analyses of key organs, tumour tissues, and incidence of lethality were determined.

C5EOSEW5050ESA at 200 mg/kg and gemcitabine combination had no additive antitumor effects compared to a single treatment. A comparably greater response in a reduction in tumour growth via a reduction of Ki-67 protein expression, and a decrease in necrosis was also demonstrated by 400 mg/kg of C5EOSEW5050ESA and gemcitabine combination compared to that of individual agents. No signs of organ toxicities were observed in any treatment group.

The combination of C5EOSEW5050ESA with gemcitabine significantly reduced the pancreatic tumour growth in mice compared to a single treatment. This study provides valuable insights into using C5EOSEW5050ESA as a complementary treatment to gemcitabine for pancreatic cancer.

Findings from this study may provide the basis for product formulation and manufacturing of botanical drugs (NuvastaticTM) to be used as complementary medicine for the treatment of pancreatic cancer patients.

ACKNOWLEDGEMENTS
Ashwaq Yehya was supported by TWAS-USM (The Academy of Sciences for the Developing World, Italy-Universiti Sains Malaysia).

FOOTNOTES
Author contributions: Yehya AHS and Subramaniam AV carried out the experiments; Yehya AHS drafted the manuscript; Yehya AHS, Asif M, and Kaur G analysed the data; Abdul Majid AMS conceived and planned the experiments; Oon CE designed the experiments, derived the model, and supervised the project; All authors have read and approved the final manuscript.

Supported by the NKEA Research Grant Scheme (NRGS) by the Ministry of Agriculture Malaysia, No. 304/CIPPM/650736/k123.

Institutional animal care and use committee statement: The animal study was approved and conducted under strict guidelines according to USM Animal Ethics Committee (Reference #: USM/Animal Ethics Approval/2016/(97) (746).

Conflict-of-interest statement: Amin Malik Shah Abdul Majid has a commercial interest in C5EOSEW5050ESA O.s extract of NuvastaticTM. All the other authors declare no financial and non-financial competing interests.

Data sharing statement: No additional data are available.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Malaysia

ORCID number: Ashwaq Hamid Salem Yehya 0000-0001-7464-1618; Ayappa V Subramaniam 0000-0002-3302-6704; Muhammad Asif 0000-0001-8989-9945; Gurjeet Kaur 0000-0002-6232-5703; Amin MS Abdul Majid 0000-0001-7499-2258; Chern Ein Oon 0000-0002-4685-6408.

S-Editor: Ma YJ
REFERENCES


7. Alissa EM. Medicinal herbs and therapeutic drugs interactions. Ther Drug Monit 2014; 36: 413-422 [PMID: 24452064 DOI: 10.1097/FDT.000000000000035]


21 Ashley C, Dunleavy A. The renal drug handbook: the ultimate prescribing guide for renal practitioners: CRC Press, 2017


